Solid Biosciences (SLDB) Operating Margin: 2022-2024
Historic Operating Margin for Solid Biosciences (SLDB) over the last 2 years, with Dec 2024 value amounting to 53,194.67%.
- Solid Biosciences' Operating Margin rose 3115011.00% to 53,194.67% in Q4 2024 from the same period last year, while for Dec 2024 it was 38,155.29%, marking a year-over-year increase of 1440769.00%. This contributed to the annual value of 38,155.29% for FY2024, which is 1446166.00% up from last year.
- According to the latest figures from Q4 2024, Solid Biosciences' Operating Margin is 53,194.67%, which was up 23.98% from 42,904.88% recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' Operating Margin registered a high of 53,194.67% during Q4 2024, and its lowest value of -1,318.03% during Q2 2022.
- Its 3-year average for Operating Margin is 27,682.08%, with a median of 26,471.07% in 2023.
- Data for Solid Biosciences' Operating Margin shows a peak YoY surged of 3,115,011bps (in 2024) over the last 5 years.
- Quarterly analysis of 3 years shows Solid Biosciences' Operating Margin stood at -1,318.03% in 2022, then spiked by 2,550,091bps to 22,044.55% in 2023, then spiked by 3,115,011bps to 53,194.67% in 2024.
- Its Operating Margin was 53,194.67% in Q4 2024, compared to 42,904.88% in Q3 2024 and 31,577.27% in Q2 2024.